US Patent 11760756 Crystalline form of a PD-1/PD-L1 inhibitor
Patent 11760756 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+55 properties)
Article (+457 characters)
US Patent 11760756 Crystalline form of a PD-1/PD-L1 inhibitor
Article
Patent abstract
The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Jiacheng Zhou
Mei Li
Pingli Liu
Shili Chen
Yongchun Pan
Yongzhong Wu
Zhongjiang Jia
Date of Patent
September 19, 2023
Patent Application Number
17520264
Date Filed
November 5, 2021
Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11760756 Crystalline form of a PD-1/PD-L1 inhibitor
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
